Kornimate/medical-research-clean huggingface dataset:
rivastigmine for methamphetamine dependent individuals

Conditions: Substance-Related Disorders

Summary: methamphetamine abuse has been steadily increasing over the past decade. rivastigmine is a medication that may be helpful in treating methamphetamine dependence. the purpose of this study is to evaluate the effectiveness of rivastigmine in treating methamphetamine dependent individuals.

methamphetamine is a powerful stimulant that affects the central nervous system. chronic methamphetamine use often leads to psychotic behavior. rivastigmine is an acetylcholinesterase inhibitor that is currently approved to treat alzheimer's-related dementia. the purpose of this study is to assess the efficacy of rivastigmine in treating methamphetamine dependent individuals. participants will be randomly assigned to either one of two dose levels of rivastigmine or placebo for 12 weeks. participants will be assessed for cardiovascular, subjective, and reinforcing effects that are produced by methamphetamine. all participants will partake in contingency management sessions through week 4.

Eligibility criteria:
inclusion criteria: * speaks english * not seeking treatment for methamphetamine dependence at study entry * meets dsm-iv criteria for methamphetamine abuse or dependence * smokes or intravenously uses methamphetamine * resting pulse between 50 and 90 beats per minute within 2 days prior to study entry * systolic blood pressure between 85 and 150 mmhg and diastolic blood pressure between 45 and 90 mmhg within 2 days prior to study entry * electrocardiogram demonstrating normal sinus rhythm, normal conduction, and no clinically significant arrhythmias * medical history and brief physical examination demonstrating no clinically significant contraindications for study participation exclusion criteria: * history or evidence of seizures or brain injury * previous adverse reaction to methamphetamine * neurological or psychiatric disorders (e.g., psychosis, bipolar illness, or major depression) * organic brain disease or dementia * history of any psychiatric disorder that requires ongoing treatment or that would make study compliance difficult * history of suicide attempts within the 3 months prior to study entry * heart disease or high blood pressure * family history of early cardiovascular morbidity or mortality * untreated or unstable medical illness, including neuroendocrine, autoimmune, liver, kidney, or active infectious disease * hiv infected * aids-defining illness * currently taking antiretroviral medication * pregnant or breastfeeding * unwilling to use an adequate method of contraception for the duration of the study * history of respiratory illness (e.g., asthma, chronic coughing, and wheezing) * currently using alpha or beta agonists, theophylline, or other sympathomimetics
to identify kras gene and safe margin in association with outcome in colorectal liver metastases following ultrasound-guided radiofrequency ablation

Conditions: KRAS Gene; Colorectal Cancer; Liver Metastasis; Safe Margin; Radiofrequency Ablation

Summary: to investigate the clinical effect of radiofrequency ablation on colorectal cancer liver metastases with different kras gene status


Eligibility criteria:
inclusion criteria: 1. diagnosed as liver metastasis of colorectal cancer; 2. there are no more than 3 liver metastases and all the lesions are not more than 5 cm; or no more than 6 liver metastases and all the lesions are not more than 3.0 cm; 3. the primary lesion of colorectal cancer has been treated curatively or is planned to undergo curative treatment; 4. kras gene test results can be obtained for primary or metastatic foci; 5. signing informed consent voluntarily; 6. men or women who have reached the age of 18; 7. ultrasound or ultrasound contrast can clearly show the lesion and guide rfa treatment; 8. platelet count\> 50,000/mm3, prothrombin activity\> 50%; 9. child-pugh grade a or b of liver disease, but no hepatic encephalopathy or/and ascites; 10. subjects are willing to return to the research center for research follow-up; 11. life expectancy ≥ 6 months- exclusion criteria: 1. suffer from but not limited to the following serious diseases: congestive heart failure, myocardial infarction or cerebrovascular accident, or life-threatening arrhythmia in the past 6 months; 2. during pregnancy or lactation. before receiving research treatment, women of childbearing age must have a negative serum pregnancy test; 3. any known allergic reactions to the intravenous imaging agent used in this study; 4. there is portal vein or hepatic vein tumor infiltration/carcinoma; 5. international normalized ratio of prothrombin\> 1.5 times the upper limit of normal value (unl) of the research center; 6. platelet count \<50,000/mm3, absolute neutrophil count \<1500/mm3, or heme value \<10.0g/dl; 7. serum creatinine ≥2.5mg/dl or calculated creatinine clearance (crcl) ≤25.0ml/min; 8. serum bilirubin\>3.0mg/dl; 9. serum albumin \<2.8g/dl; 10. body temperature \>101°f (38.3°c) immediately before study treatment; 11. being treated with other research drugs; 12. heart failure nyha function grade is iii or iv .
prospective study on the value of subcutaneous drains in gastrointestinal surgery

Conditions: Digestive System Diseases [C06]; Digestive System Neoplasms [C04.588.274]

Summary: the aim of the study is to determine wether subcutaneus suction drain (type redon-drain) protect against surgical side infection by laparotomy in general surgery.

if subcutan drains inserted during wound closudsure after laparotomy avoid subcutaneous haematoma and seromas by suction, these drains shout protect against surgical site infections. this is the ratio why such drain are in use in many countries. to test whether this hypothesis is true or not we pland this study.

Eligibility criteria:
inclusion criteria: * indication for laparotomy * age older 18 years * informed consent exclusion criteria: * organ transplantation * operation for abdominal hernia * appendectomy by mcburney incision * redo-operation

Keywords: laparotomy surgical site infection drainage
telestroke for comprehensive transient ischemic attack care in acute stroke ready hospitals

Conditions: Transient Ischemic Attack

Summary: telecast-tia is a prospective single-center study evaluating guideline-based transient ischemic attack (tia) treatment at an acute stroke ready hospital (asrh) pre- and post-initiation of a specialist telestroke inpatient rounding service. telecast-tia will study the following clinical endpoints: diagnostic stroke evaluation, secondary stroke prevention, health screening and evaluation, stroke education, inpatient complications, and stroke recurrence rates. additional relevant non-clinical data will include patient and provider satisfaction scores, transfer patterns, and a cost analysis.

telestroke is a validated intervention that improves the triage and emergent treatment of acute stroke, specifically related to the use of intravenous thrombolysis. effective urgent stroke evaluation and secondary stroke prevention is also essential to decrease the risk of recurrent stroke, however, there have been no studies to date examining the use of telestroke to improve delivery of non-emergent inpatient stroke care per american heart association (aha) guidelines. currently, access to stroke specialist expertise is limited resulting in significant disparities in stroke care. previous publications have identified that patients in rural areas may receive sub-optimal stroke care that does not follow accepted guideline recommendations. telestroke is a cost-effective mechanism to deliver specialist stroke care to hospitals that do not have in-person stroke consultation available. the aim of telecast-tia is to determine whether specialist telestroke inpatient rounding improves guideline-based tia treatment when compared to non-specialist transient ischemic attack treatment. the primary outcome of telecast-tia is a composite score of 3 categories: diagnostic stroke evaluation, secondary stroke prevention, and stroke education. individual components of the primary outcome were principally derived from aha stroke guidelines. additional outcome measures include individual analyses of the components of the primary outcome as well as the complication rate, stroke recurrence rate, transfer rate, patient and provider satisfaction levels, and a cost-analysis. all outcomes will be assessed at 1 year post-implementation, with data accruement starting after a 3-month lead in phase.

Eligibility criteria:
inclusion criteria: * age 18 and above * patients with the primary diagnosis of transient ischemic attack evaluated at the fairview ridges hospital emergency room * clinical diagnosis of transient ischemic attack by the treating stroke neurology service exclusion criteria: * patients less than 18 years old * patients who leave the hospital against medical advice * patients who are felt to have an alternative diagnosis

Keywords: telestroke telemedicine secondary stroke prevention
safety study of 89zr-anti-cldn18.2 mabs pet imaging in patients with cldn18.2 positive solid tumors

Conditions: Solid Tumor, Adult

Summary: this is a single arm study to evaluate the safety and biodistribution of 89zr-labeled anti-cldn18.2 mabs (89zr-ny005) pet imaging in patients with cldn18.2 positive solid tumors.

after being fully informed about the study and potential risks, all patients giving written informed consent will be evaluated to determine eligibility for study entry. patients will receive an injection of anti-cldn18.2 mabs(89zr-ny005) and will undergo pet/ct scanning to determine uptake of 89zr-ny005 in tumor lesions and normal tissues and organs.

Eligibility criteria:
inclusion criteria: 1. patients voluntarily signed informed consent, and be able to complete the trial according to the requirement of the scheme; 2. aged 18-80, male or female; 3. the clinical diagnosis was gastric cancer, esophageal cancer and pancreatic cancer; 4. patients with biopsy-proven cldn18.2 positive; 5. patients diagnosed with solid tumors confirmed by histopathology or cytology test; 6. at least two measurable solid lesions has been examined by 18f-fdg pet/ct (recist1.1 standard); 7. ecog score ≤ 0\~3; life expectancy of at least 3 months; 8. alt, ast shall not exceed 3 times of the normal upper limit; bun, cr not exceed 1.5 times of the normal upper limit. 9. other routine examinations are within the normal range or considered acceptable by the researchers. exclusion criteria: 1. recovery from major trauma (including surgery) within 4 weeks prior to study treatment; 2. patients with systemic or locally severe infections, or other serious coexisting diseases; 3. patients with abnormal immune function or who have recently used immunosuppressive or potentiating agents including various vaccines; 4. patients with autoimmune diseases, including rheumatoid arthritis; 5. inadequate control of arrhythmias, including atrial fibrillation; 6. uncontrolled hypertension; 7. patients with allergies or allergies to any component of the imaging agent or antibody; 8. patients who cannot undergo pet/ct imaging scan; 9. syphilis, hbv, hcv, or hiv positive subjects; 10. male and female subjects of reproductive age cannot take effective contraceptive measures; 11. pregnant or lactating women; 12. patients with a history of mental illness or related conditions; 13. other subjects considered unsuitable by researchers.
an evaluation of the safety and efficacy of moxifloxacin ophthalmic solution 0.5% ((vigamox®) versus ofloxacin ophthalmic solution 0.3% in the treatment of bacterial conjunctivitis in chinese patients

Conditions: Bacterial Conjunctivitis

Summary: the purpose of this study is to evaluate moxifloxacin 0.5% relative to ofloxacin 0.3% in the treatment of bacterial conjunctivitis in chinese patients.


Eligibility criteria:
inclusion criteria: * chinese. * diagnosis of bacterial conjunctivitis based on clinical observation. * understand and sign the approved informed consent. legally authorized representative can provide informed consent for patients less than 18 years old and/or incapable of understanding the informed consent. * willing to complete all required study procedures and visits. * other protocol-defined inclusion criteria may apply. exclusion criteria: * women who are pregnant, lactating, or planning a pregnancy. * only 1 sighted eye or vision not correctable to 0.6 logmar or better in either eye. * planned contact lens wear during the course of the study. * signs and symptoms of bacterial conjunctivitis for longer than 4 days prior to screening (day 1). * suspected fungal, viral, or acanthamoeba infection. * any systemic or ocular disease or disorder, complicating factor or structural abnormality that would negatively affect the conduct or outcome of the study. * history of recent surgery. * presence of concomitant systemic viral infection. * other protocol-defined exclusion criteria may apply.

Keywords: bacterial conjunctivitis anti-infective antibiotics
evaluation of fluid output threshold for safe chest tube removal - a potential way to decrease length of stay in hospital and to improve postoperative care after lung surgery?

Conditions: Pleural Effusion Recurrence; Pulmonary Resection; Chest Tube Management

Summary: previous studies have shown that the removal of the chest tube after lung surgery significantly improves pain symptoms and lung function. the criteria for chest tube removal still remain vague in modern thoracic surgery and rely on personal experience instead of evidence-based criteria. every hospital has its own traditional standard fluid threshold and believes in that without adapting and comparing it not even after introduction of newer and more minimal-invasive operation technique. according to literature the traditional fluid threshold is varying from 100 to 500 or even more millilitre in 24 hours. since pleural fluid resorption is proportional to body weight the investigators believe that a body weight related approach of chest tube management would improve safety and would allow an earlier chest tube removal without a higher rate of complication. in this way the investigators believe in improving pain management and in achieving earlier discharge of the patient.


Eligibility criteria:
inclusion criteria: * lobectomy/ bilobectomy * segmentectomy * signed consent * age of majority exclusion criteria: * pneumonectomy * atypical resections * empyema * pleural effusion (not related to surgery) * pleurodesis * pregnancy
dce-mri guided neoadjuvant chemotherapy for borderline resectable pancreatic cancer

Conditions: Borderline-resectable Pancreatic Cancer

Summary: the goal of this study is to test whether chemotherapy guided by a new imaging method named dce-mri can more effectively reduce a pancreatic tumor, enabling curable surgery, over the conventional method when a tumor is categorized as borderline resectable pancreatic cancer. uab radiological research team has been studying a cutting-edge imaging technique named dynamic contrast-enhanced magnetic resonance imaging, or dce-mri, for over 10 years. this technique has been globally used to calculate the blood flow of various tissues, including tumors. blood flow often serves as a critical indicator showing a disease status. for example, a pancreatic tumor typically has low blood flow, so it can be used as an indicator to identify the presence of a pancreatic tumor. in addition, an effective therapy can result in the increase of blood flow in a pancreatic tumor during the early period of treatment. therefore, the investigators may be able to determine whether the undergoing therapy is effective or not by measuring the change of blood flow in the pancreatic tumor and deciding whether to continue the therapy or try a different one.


Eligibility criteria:
inclusion criteria: * adult patients (age 19 years or older). * patients with newly diagnosed and untreated borderline resectable pancreatic cancer. * patients with signed informed consent. exclusion criteria: * any history of prior radiation or chemotherapy or surgical removal for pancreatic cancer. * participants with safety contraindications to mri examination (determined by standard clinical screening). * participants who are pregnant, lactating or are planning to become pregnant during the study. * participants who are planning to father a child during the study.
prevention of varicella zoster virus (vzv)-reactivation in hiv-positive individuals enrolled in a prospective immunogenicity and safety trial of vzv vaccine: prove-it-study

Conditions: Herpes Zoster

Summary: the goal is to demonstrate the immunogenicity and safety of zostavax® in hiv positive individuals. study participants are stratified into different patient groups according to their cd4 cell count, viral load and hiv status. * trial with medicinal product * trial with immunomodulatory product / biological


Eligibility criteria:
inclusion criteria: all individuals * age \>18 years * male, or female with negative urine pregnancy test * vzv-seropositive (serologically documented) * agree to use a barrier method of birth control (such as a condom) * written informed consent hiv positive individuals on art (group a1-a3) * continuous art for \>3 months before baseline * no change of art regimen within 1 month before baseline * hiv-rna (value must be \<3 months old )\<50 copies/ml at last visit * cd4-count (value must be \ 500 cells/µl for group a1, 350-500 cells/µl for group a2 and 250 -349 cells/µl for group a3 * participation in the shcs hiv-positive individuals without art (group b) * hiv-1 rna \>1000 copies/ml (\<3 months before baseline) * cd4-cell count \>500 cells/µl (\<3 months before baseline) * participation in the shcs healthy hiv-negative volunteers (group c) * negative hiv-screening test (\<3 months before baseline) * cd4 cell count \>500 cells/µl exclusion criteria: common exclusion criteria * contraindications on ethical grounds * involvement in a conflicting (vaccine or investigational drug) clinical trial (except from the participation in the swiss hiv cohort study). * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders or dementia of the subject. * pregnancy or breast feeding. * other clinically relevant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc), * known or suspected non-compliance, drug- or alcohol abuse. specific exclusion criteria * fever \> 38.3 °c or acute illness during the last 4 weeks * exposure to chickenpox or shingles within four weeks prior to study entry * history of shingles * immunosuppression due to disease (other than hiv) or due to medication within 30 days of study entry (eg corticosteroids) * household contact with known immunodeficiency (e.g. hiv-positive with cd4 \<250 cells/µl) * immunoglobulin or blood product treatment within 1 year prior or 2 month after study vaccination * previous allergic reaction to vaccine components (i.e. neomycin or gelatin) * vaccination with a life attenuated vaccine one month prior to study entry * history of chickenpox vaccination * treatment with anti-herpes drugs 4 weeks before baseline * severe coagulation disorder or oral anticoagulant treatment * laboratory exclusion criteria. * thrombocytopenia \< 50x 103/?l * haemoglobin \<12 g/dl * more than threefold elevation of alt * creatinine of more than150 µmol/l * glucose \>10 mmol/l

Keywords: hiv vzv (varicella zoster virus) vaccine t cell immunogenicity safety
ht-0712 vs. placebo in subjects with age-associated memory impairment (aami)

Conditions: Age-Associated Memory Impairment (AAMI)

Summary: this is a phase 2 randomized, multicenter, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy of ht-0712 in improving memory and cognitive performance in subjects with age-associated memory impairment (aami)


Eligibility criteria:
main inclusion criteria: * complaints of memory loss in everyday life * performance at least one standard deviation below the mean established for young adults on standardized memory tests * absence of dementia * intact global intellectual function main exclusion criteria: * diagnosis of mild cognitive impairment (mci) or alzheimer's disease * evidence of dementia * evidence of psychiatric or neurological disorder that could influence cognition or contributed to the subject's memory loss * use of any drugs that could influence cognition
effect of lidocaine in antiarrhythmic dosage on postoperative cognitive dysfunction in supratentorial craniotomy dysfunction in supratentorial craniotomy

Conditions: Supratentorial Craniotomy Dysfunction

Summary: the purpose of this study is to investigate the effect of lidocaine in antiarrhythmic dosage on postoperative cognitive dysfunction in supratentorial craniotomy.


Eligibility criteria:
inclusion criteria: * 18-60 years old, asa physical status i or ii, bmi\<30 * scheduled for elective supratentorial craniotomy * mmse\<24 before operation * cooperative and given informed consent in person exclusion criteria: * history of mental or psychiatric disorders * contraindicated to internal jugular venous catheterization * pregnant or lactating female * history of systemic malignant tumor or diabetes * previously treated with this protocol or participated in another study within previous 30 days * suspected history of allergic reaction or intolerance to amides or other anesthetic agents in this study * history of alcohol abuse and/or drug abuse within previous one year * history or a family history of malignant hyperthermia

Keywords: supratentorial craniotomy
outcome study following reimbursement changes in the use of fixed combination inhalers in patients with asthma or chronic obstructive pulmonary disease

Conditions: Asthma; Chronic Obstructive Pulmonary Disease

Summary: to investigate how a switch from fixed combination treatment (ics and laba) to other treatments influence asthma or copd treatment failure


Eligibility criteria:
inclusion criteria: * all patients who was on treatment with fixed combination asthma or copd therapy by january 1 2010

Keywords: epidemiological asthma copd reimbursement switch outcomes associated with the change in reimbursement
the association between conditioned pain modulation and pain catastrophizing in chronic low back pain

Conditions: Catastrophizing Pain; Pain, Somatic; Chronic Low Back Pain

Summary: this study evaluates the potential association between pain catastrophizing thoughts and the ability to dampen pain via endogenous descending inhibition. half of the participants are persons with chronic low back pain and the other half are age and gender-matched controls

pain catastrophizing is a cognitive feature commonly seen in various musculoskeletal pain population and is considered an important factor to account for in rehabilitation. the ability to dampen pain via endogenous pain modulatory mechanisms is likewise known to be reduced in musculoskeletal pain conditions. studies utilizing functional magnetic resonance imaging (fmri) have demonstrated that the supraspinal areas involved in pain-related cognitive processing to a great extent overlap with those involved in endogenous pain modulation. therefore, it is plausible that factors such as pain catastrophizing thoughts may affect the nervous systems ability to dampen pain. chronic low back pain is the single clinical problem with the biggest impact in the modern society. previous studies have demonstrated that pain catastrophizing and reduced endogenous pain inhibition are part of the clinical picture. however, previous studies have never investigated a potential relationship between these two factors.

Eligibility criteria:
inclusion criteria: low back pain group: * chronic low back pain ( lasting more than 3 months) * intensity of ≥ 3/10 on a numeric rating scale * pain is located in the area between the gluteal folds below to the thoracolumbal junction above. controls: no current or previous history of musculoskeletal pain of ongoing nature exclusion criteria: applies for both groups: * signs of radicular pain or other specific medical conditions e.g. rheumatologic disease or diabetes * pregnancy